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SUMMARY. Lipid droplets are intracellular organelles involved not only in lipid storage, 
but also in cell signalling and the regulation of intracellular vesicular trafficking. Recent basic 
studies have suggested that interactions between hepatitis C virus (HCV) core protein and 
lipid droplets are required for the HCV infection cycle. In infected cells, the HCV core protein 
is associated with the surface of lipid droplets and the endoplasmic reticulum membranes 
closely surrounding these droplets, and its self-assembly drives virion budding. This 
interaction also seems to be directly linked to a virus-induced steatosis, which involves the 
deposition of triglycerides in the liver and contributes to the progression of fibrosis in patients 
with chronic hepatitis C. Many clinical studies have reported that virus-induced steatosis is 
significantly more severe with HCV genotype 3 than with other genotypes, and this 
phenomenon has been modelled in recent basic studies based on the production of HCV core 
proteins of various genotypes in vitro. The association of HCV core protein with lipid droplets 
seems to play a central role in HCV pathogenesis and morphogenesis, suggesting that virus-
induced steatosis may be essential for the viral life cycle. 
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INTRODUCTION 
Hepatitis C virus (HCV) has a major impact on public health, with an estimated 170 million 
infected individuals worldwide [1]. HCV infection is a major cause of chronic liver disease: 
more than 50% of individuals exposed to HCV develop chronic hepatitis and 20 % of 
chronically infected individuals develop cirrhosis. HCV infection is also a major cause of 
hepatocellular carcinoma and the primary reason for liver transplantation in Western Europe 
and the United States. No vaccine protecting against HCV infection has yet been developed, 
and current antiviral strategies are of limited efficacy and have major side effects [2]. HCV is 
a small enveloped RNA virus belonging to the Flaviviridae family, genus Hepacivirus. This 
virus is highly heterogeneous and has been classified into six major genotypes and numerous 
subtypes [3]. Its has a single-stranded RNA genome of positive polarity encoding a single 
polyprotein precursor of just over 3000 amino-acid residues, flanked by structured 5’ and 3’ 
untranslated regions (UTRs) essential for RNA replication and translation (Figure 1) [4]. The 
HCV polyprotein is cleaved co- and post-translationally by cellular and viral proteases to 
yield 10 mature structural and nonstructural proteins (Figure 1). The structural proteins of 
HCV - the core (C) and the two envelope glycoproteins E1 and E2, released by the host cell 
signal peptidase and the signal peptide peptidase (SPP) – are the basic components of the viral 
particle. The non-structural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) are 
involved in proteolytic processing of the residual polyprotein and HCV genome replication, 
and are not incorporated into the viral particle. The structural proteins are separated from the 
nonstructural proteins by the short membrane peptide p7, which is thought to be a viroporin. 
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MODEL SYSTEMS FOR STUDYING THE LIFE CYCLE OF HCV IN VITRO 
Since the cloning of the viral genome in 1989, considerable progress has been made towards 
characterizing the viral genome and proteins, using heterologous expression systems. In sharp 
contrast, little is known about the life cycle of HCV because, until recently, no system 
supporting HCV replication and particle formation in vitro was available. Viruses are obligate 
intracellular parasites, so studies of their multiplication cycle require a permissive host cell. 
Many attempts were made to propagate HCV in cell culture, although these attempts were 
entirely unsuccessful for many years [5]. Alternative cellular models were therefore 
established for studies of individual steps in the HCV lifecycle. The first such model consisted 
of subgenomic HCV RNAs containing sequences encoding the non-structural proteins flanked 
by the 5’ and 3’ UTRs [6, 7]. These subgenomic RNAs, called replicons, were able to self-
replicate in the human liver hepatoma cell line Huh7, and this replication was dependent on 
adaptative mutations affecting sites in the non-structural proteins. This system provided the 
first opportunity for studies of efficient HCV RNA replication in vitro and evaluations of the 
effect of antiviral drugs targeting the translation or replication of viral RNA [8, 9]. 
Ultrastructural studies of Huh7 cells harboring such HCV replicons demonstrated the 
presence in these cells of specific endoplasmic reticulum (ER) membrane alterations, 
resulting in a membranous web containing the viral replication complex [10]. Another model, 
based on the pseudotyping of retroviruses with the two HCV envelope glycoproteins E1 and 
E2, has proved a powerful tool for functional studies of HCV binding to and entry into Huh7 
cells and other human liver cell lines [11, 12]. These pseudotyped retroviral particles differ 
from native serum-derived HCV virions, but studies with such particles identified both CD81 
and SR-BI as potential high-affinity receptor candidates [13]. HCV-like particles (HCV-LPs) 
obtained by expressing genes encoding HCV structural proteins in mammalian cells have 
been used as an alternative model for studying HCV morphogenesis [14, 15]. Studies with 
HCV core, lipid droplets and steatosis  - Page 5                                                                                                                  
  
this HCV-LP model have demonstrated that HCV budding occurs at the ER membrane and is 
driven by the core protein [16, 17]. 
 Finally, a milestone in HCV research was achieved with the recent development of a 
cell culture system for HCV propagation, resulting in the production of significant levels of 
infectious virus particles [18-20]. This development built on the initial finding that a unique 
clone derived from a genotype 2a viral isolate from a Japanese patient with fulminant 
hepatitis (JFH-1) replicated strongly in the absence of adaptative mutations in the replicon 
model [21]. Wakita et al. demonstrated that RNA transcripts from the full-length JFH-1 
genome could generate viruses in Huh7 cells that were capable of infecting naive Huh7 cells 
[18]. Moreover, the viral particles produced by these cells were infectious in a chimpanzee, 
confirming the authenticity of the HCV particles generated during cell culture [18]. Studies of 
individual steps in the viral life cycle (entry, replication and morphogenesis) remain difficult 
and sometimes no easier with this model than with the other models described above [22, 23], 
but this model does provide the first opportunity to study the complete viral life cycle in vitro.  
 
MODEL SYSTEMS FOR STUDYING HCV PATHOGENESIS IN VIVO 
The restricted host range of HCV has hampered the development of a suitable small-animal 
model of viral replication and pathogenesis. Indeed, chimpanzees remain the only recognised 
animal model for studying HCV [24]. The main advantage of using the chimpanzee as an 
animal model for HCV infection is that disease progression follows a clinical course similar 
to that seen in human patients. Both HCV-infected chimpanzees and human patients display 
long-term liver damage, characterized by the formation of similar necroinflammatory hepatic 
lesions and changes in hepatocyte morphology [25]. However, this model is limited by its 
high cost and, above all, ethical considerations. Other primates do not appear to be 
reproducibly susceptible to HCV infection, but the related GB virus B (GBV-B), a more 
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recently discovered member of the Flaviviridae family, can be transmitted to tamarins and 
may represent a valuable surrogate model for HCV [26]. Attempts to develop a small-animal 
model have met with limited success, with only transient HCV replication being reported in 
the HCV-Trimera and chimeric SCID-Alb/uPA Hepatech mouse models [27-31]. Several 
transgenic mouse models have been developed for studies of the potentially pathogenic effect 
of HCV proteins on hepatocytes. However, these studies have yielded conflicting results. 
Some studies have shown that the core and envelope proteins have no pathogenic effect [32, 
33], whereas others have shown that mice expressing the core protein develop hepatic 
steatosis, lymphocyte infiltration, hepatocyte necrosis and hepatocellular carcinoma [34, 35]. 
 
LIPID DROPLETS 
Lipid droplets are intracellular storage organelles found in all eukaryotic organisms. They 
consist of a core of neutral lipid, comprising mainly triacylglycerols and/or cholesterol esters, 
surrounded by a monolayer of phospholipids [36]. The phospholipid layer is bounded by a 
proteinaceous coat. In mammalian cells, the principal lipid droplet-binding proteins identified 
to date are adipophilin, TIP47 and a family of related proteins, the perilipins. Adipophilin and 
TIP47 are present in a wide range of cell types, whereas perilipins are restricted to adipocytes 
and steroidogenic cells [37]. On electron microscopy (EM), lipid droplets appear as grey 
amorphous circular masses, usually surrounded by a darker rim (Figure 2). However, rather 
than inert inclusions, they should be considered as metabolically active and mobile organelles 
participating in a range of functions other than lipid homeostasis, including cell signaling, and 
the regulation of intracellular vesicular trafficking and membrane compartments [38]. All cell 
types have the ability to generate lipid droplets in response to high fatty acid levels, and to 
metabolise and disperse these lipid droplets when the conditions are reversed. However, their 
biogenesis is poorly understood. It has been suggested that neutral lipid accumulation within 
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the lipid bilayer of the ER membrane induces the budding of an independent organelle, 
surrounded by the phospholipid monolayer originating from the cytoplasmic leaflet of the ER 
membrane [39]. It remains unknown whether mature lipid droplets stay in physical contact 
with the ER, or bud to form a completely independent organelle [38]. Lipid droplet-associated 
proteins are thus thought to be at least partly derived from proteins resident in the ER 
membrane [36]. However, this model was recently called into question by a three-dimensional 
EM study which suggested that the biogenesis of lipid droplets occurred in specialised cup-
shaped regions of the ER [40].   
 
HCV CORE PROTEIN ASSOCIATION WITH LIPID DROPLETS 
A link between lipid droplets and HCV was first suggested 10 years ago, when the HCV core 
protein was produced in vitro in various cell types, using heterologous expression systems. 
These studies showed that the HCV core protein was cytoplasmic, and either associated with 
the ER membrane or on the surface of lipid droplets [41, 42]. Subsequent studies have 
confirmed these observations [43], but some studies have also reported the presence of the 
HCV core protein in the nucleus
 
[44] or mitochondria [45]. Interestingly, although the HCV 
core protein is very difficult to detect by immunocytochemistry in biopsy samples from 
infected patients, it seems to have a discrete granular distribution in the cytoplasm
 
[46, 47], 
which may be explained by its association with lipid droplets.  
 The HCV core protein is produced at the N-terminal end of the polyprotein and is 
followed by the signal sequence of the E1 envelope glycoprotein. The signal sequence targets 
the nascent HCV polyprotein to the ER, allowing the translocation of E1 to the ER lumen, an 
essential step in the membrane-dependent processing of the core protein. Cleavage by a signal 
peptidase in the ER lumen releases the N-terminal end of E1, leaving the 191aa core protein 
anchored by the signal peptide [48]. This 191 aa polypeptide is an immature form of the core. 
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It is further processed by an intramembrane protease, the signal peptide peptidase (SPP), 
which cleaves within the C-terminal signal peptide and releases the N-terminal 173-179 aa of 
the core protein from the ER (Figure 1). This cleaved core protein remains associated with the 
cytoplasmic monolayer of the ER membrane via a hydrophobic domain located between aa 
120 and aa 175 [17, 49]. This enables it to move along this monolayer towards the surface of 
the lipid droplets [48]. This hydrophobic domain, which mediates targeting to the lipid 
droplets, is not found in the core protein of related pesti- and flaviviruses, with the exception 
of GB virus B (GBV-B), the virus most closely related to HCV [17, 50]. The role of the 
association between HCV core and lipid droplets in the viral life cycle remains unknown. 
However, studies in the HCV-LP model have recently shown that SPP cleavage is required 
not only for the trafficking of the HCV core to the lipid droplet surface, but also for its self-
assembly and budding at the ER membrane [51]. Studies in this model have shown that the 
HCV core protein self-assembles in HCV-LPs in ER membranes, which often appear to be 
located very close to the lipid droplets (Figure 3). Unfortunately, it was extremely difficult to 
document viral assembly and morphogenesis by similar EM studies in cell culture systems in 
which the JFH-1 virus is efficiently propagated [22].  However, early studies of cells infected 
with the JFH-1 virus showed that the core protein was detected at the surface of lipid droplets 
or in association with the ER membranes surrounding the lipid droplets [22]. In these cells, 
the HCV core protein was never detected in the nucleus or mitochondria [22]. More recently, 
it has been shown that the lipid droplets are directly involved in the production of infectious 
JFH-1 virus particles [52]. The authors demonstrated that the HCV core protein recruits non-
structural proteins and replication complexes to lipid droplet-associated membranes, and that 
this recruitment is essential for producing infectious viruses. In another study, disrupting the 
association of HCV core protein with lipid droplets was correlated with a loss in production of 
the JFH-1 virus [53]. These observations suggest that the association between the HCV core 
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protein and lipid droplets plays a critical role at some stage of virion morphogenesis. It is 
possible that the ER membrane supporting lipid droplet formation provides a platform for 
nucleocapsid assembly, by concentrating the viral and/or cellular factors required for viral 
assembly, and/or by excluding those that inhibit this process. 
 
HCV CORE PROTEIN AND STEATOSIS 
Studies based on the use of heterologous expressions systems have shown that the HCV core 
protein interacts with a broad range of cellular proteins and influences numerous host cell 
functions including gene transcription, the inhibition or stimulation of apoptosis, cell 
signaling and the suppression of host immunity [54, 55]. This protein also plays a role in lipid 
metabolism, as it has been shown to bind and activate the DNA-binding domain of the 
retinoid receptor  (RxR), a transcriptional regulator controlling many cellular functions, 
including cellular lipid synthesis [56, 57]. The HCV core protein also decreases expression of 
the peroxisome proliferators-activated receptor  (PPAR), a nuclear receptor regulating 
several genes responsible for fatty acid degradation [56]. HCV-infected patients have recently 
been shown to have lower than normal levels of PPAR mRNA in their liver [58, 59]. 
Nonetheless, the relevance of these in vitro experiments, mostly involving heterologous 
overexpression, to the natural course and pathogenesis of HCV infection, remains unclear. 
 As reported above, the HCV core protein has been implicated in lipid accumulation in 
the liver of some lines of transgenic mice. The mechanism underlying this liver steatosis in 
transgenic mice remains a matter of speculation, but it has been suggested that HCV core 
protein inhibits microsomal triglyceride transfer protein (MTP) activity [60]. MTP plays a key 
role in very-low density lipoprotein (VLDL) assembly. The inhibition of this enzyme would 
therefore result in the accumulation of triglycerides. However, no interaction of the HCV core 
protein with MTP has been demonstrated, and this inhibition may be indirect. It has also been 
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suggested that HCV core protein may accumulate in the mitochondria and induce liver 
damages, by producing reactive oxygen species (ROS), these effects being prevented by a 
mitochondrial electron transport inhibitor [61]. An increase in the level of intrahepatic lipid 
peroxidation products was observed in response to carbon tetrachloride in one transgenic 
mouse model [62]. ROS production may result in the peroxidation of membrane lipids and 
proteins involved in trafficking and secretion, inhibiting VLDL secretion. In another 
transgenic mouse model, it was suggested that the effect of HCV core protein on steatogenesis 
might be related to its interaction with the nuclear proteasome activator PA28, leading to the 
up-regulation of genes encoding proteins involved in fatty acid biosynthesis [63]. However, 
the HCV core protein is not detected in the nucleus or mitochondria of cells supporting the 
JFH-1 virus life cycle, and the relevance of these particular localizations remains debated 
[22]. This raises the interesting possibility that the localization of HCV core protein on the 
surface of lipid droplets may be directly linked to liver steatosis. Although core protein is 
difficult to detect in biopsy samples from infected chimpanzees, as in those from humans, it 
was found to be associated with lipid droplets in the liver of chimpanzees displaying fatty 
change [42]. 
 Most HCV-associated liver injury results from the host immune response [64], but 
liver steatosis, which involves the deposition of triglycerides, may contribute to the 
progression of fibrosis in patients with chronic hepatitis [65-70]. Liver steatosis occurs in 
more 50% of patients with chronic hepatitis C [71]. It may be related to host metabolic factors 
(excess weight, diabetes, hyperlipidaemia, excessive alcohol intake), but many studies have 
clearly demonstrated a significant association between HCV genotype 3 and the presence of 
steatosis [72-77]. In patients infected with viruses of genotypes other than 3, steatosis seems 
to be mostly metabolic in origin, with little effect of HCV viral load. In contrast, in cases of 
genotype 3 infection, the presence of steatosis is directly correlated with serum and 
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intrahepatic titers of HCV RNA. Interestingly, the outcome of steatosis matches the 
virological response to treatment in patients infected with HCV genotype 3 with purely virus-
induced steatosis but not in patients with metabolic causes of steatosis, generally infected with 
other genotypes [78, 79].  However, both types of steatosis (viral and metabolic) may well co-
exist in at least some chronic hepatitis C patients, although steatosis is more likely to be 
predominantly viral in origin in patients infected with genotype 3 viruses and predominantly 
metabolic in patients infected with viruses of other genotypes [80, 81]. 
 The steatosis observed in HCV-positive chronic hepatitis has the potential to affect the 
natural course of the infection through different routes. One study based on the analysis of 
paired liver biopsies from patients with chronic hepatitis C clearly showed that worsening of 
steatosis was the only independent factor associated with hepatic fibrosis progression [66]. 
Recently, a meta-analysis of more than 3000 patients with chronic HCV infection in databases 
in Europe, Australia and the USA confirmed the role of steatosis as significantly and 
independently associated with fibrosis in these patients [82]. The role of liver steatosis in 
chronic hepatitis C is further extending into the area of the complications of chronic liver 
diseases. Recent evidence suggests that HCV-related steatosis may contribute to liver 
carcinogenesis. In one study investigating risk factors for the development of hepatocellular 
carcinoma (HCC) in HCV-positive patients, the presence of steatosis was significantly 
associated with the incidence of HCC in a multivariate analysis [83]. 
 Most in vitro studies using transfected cells and transgenic mouse models addressing 
the role of HCV core protein in lipid accumulation have been conducted with constructs 
derived from isolates of HCV genotype 1. Recent in vitro studies have therefore investigated 
whether an HCV core protein of genotype 3 increases the level of lipid accumulation [84-86]. 
One study demonstrated that lipid droplet accumulation occurred with core proteins from all 
viral genotypes, but the genotype 3 core protein resulted in the accumulation of larger 
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numbers of lipid droplets than the genotype 1 core protein [84]. In a subsequent study, a 
genotype 3-specific residue (phenylalanine 164, this residue being replaced by a tyrosine in 
all non-3 genotypes) present in the hydrophobic domain of the HCV core protein known to 
interact with lipid droplets, replaced the equivalent residue in the genotype 1 core protein 
[85]. This resulting Y164F mutant had a significant higher level of lipid droplet accumulation, 
consistent with the clinical evidence showing that viral core sequences have a direct effect on 
genotype 3-specific steatosis [85]. Structural studies on the HCV core protein have suggested 
that the residue in position 164 is part of an -helix present at the interface of the two 
phospholipid layers of the ER membrane [49, 87], which is presumed to be the site of lipid 
droplet morphogenesis. Phenylalanine is more hydrophobic than tyrosine and may be 
involved in lipid interactions. The presence of this residue in the core protein of genotype 3 
may therefore increase the affinity of the protein for the lipids present between the leaflets of 
the ER membrane, ultimately leading to higher levels of lipid droplet formation. However, 
other mechanisms may also be involved in this phenomenon. It has been suggested that the 
Y164F mutant up-regulate the promoter activity of the gene encoding fatty acid synthase 
(FAS), a major enzyme involved in de novo lipid synthesis, by interacting with the 
transcription factor sterol response element binding protein-1 (SREBP-1) [86].   
 
CONCLUSION 
The association of the HCV core protein with lipid droplets is probably involved in the virus-
induced steatosis. This association is also shown to be essential for the virion production, 
using the recently developed cell culture system supporting HCV propagation, and this 
suggests that virus-induced steatosis may be essential for the viral life cycle. Alternatively, the 
interaction of the HCV core protein with lipid droplets may play a role in the formation and 
release of subviral or hybrid particles, which have been shown to circulate in the serum of 
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chronically infected patients, bound to lipoproteins in the form of lipo-viro-particles (LVPs) 
[88, 89]. These particles appear as large lipoprotein-like structures enriched in apoB, apoE 
and triglycerides, containing HCV core protein and carrying viral envelope proteins at their 
surface [90]. However, the role of these LVPs in HCV biology and their contribution to the 
viral spread remain largely unknown. It is expected that the recently developed cell culture 
system in which HCV propagation has been reported in vitro will help to resolve these major 
issues. 
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Fig.1 Hepatitis C virus (HCV) genome organization and schematic representation of the 
processing of the HCV structural proteins. 
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Fig.2 Electron micrograph of a liver biopsy showing a large lipid droplet (LD). 
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Fig.3 Electron micrographs of BHK-21 (baby hamster kidney) cells producing HCV-like 
particles (HCV-LPs) at low (A) and high (B) magnifications. The HCV core protein, 
visualised here by immunolabelling with gold particles, is present at the surface of the lipid 
droplets (LD) and in the convoluted ER membranes surrounding these lipid droplets. HCV-LP 
budding (arrows) occurs at the ER membrane surrounding these lipid droplets. 
 
 
 
 
 
